• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Oncology letters >Treatment of pulmonary epithelioid hemangioendothelioma with combination chemotherapy: Report of three cases and review of the literature
【24h】

Treatment of pulmonary epithelioid hemangioendothelioma with combination chemotherapy: Report of three cases and review of the literature

机译：联合化疗治疗肺上皮样血管内皮瘤三例报告并文献复习

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

No standard therapy for pulmonary epithelioid hemangioendothelioma (PEH) has yet been established due to the rarity of the disease, the lack of clear standards for treatment and the partial-to-complete spontaneous regression. This report describes three cases of PHE manifested as bilateral intrapulmonary masses with an initial diagnosis conducted by thoracoscopic lung biopsy. These patients demonstrated a partial response to combination chemotherapy with carboplatin, paclitaxel, bevacizumab or endostar, and an improvement in clinical status. Furthermore, we reviewed the literature regarding such patients who received chemotherapy and immunotherapy; this indicated that patients with PEH demonstrated a good partial response to chemotherapy with carboplatin, paclitaxel, bevacizumab, thalidomide and a-interferon. Overall, combination chemotherapy regimens may hold therapeutic potential for the treatment of this rare disease.
机译：由于该病的罕见性，缺乏明确的治疗标准以及部分至完全的自发消退，目前尚未建立针对肺上皮样血管性血管内皮瘤（PEH）的标准疗法。该报告描述了三例PHE表现为双侧肺内包块，并通过胸腔镜肺活检初步诊断。这些患者表现出对联合用卡铂，紫杉醇，贝伐单抗或endostar化疗的部分反应，并且临床状况有所改善。此外，我们回顾了有关接受化学疗法和免疫疗法的这类患者的文献。这表明PEH患者对卡铂，紫杉醇，贝伐单抗，沙利度胺和α-干扰素的化疗表现出良好的部分反应。总体而言，联合化疗方案可能具有治疗这种罕见疾病的治疗潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号